Category: Clinical Trials
Manual data review, query management, and medical coding consume staff time and delay database lock.
Getting from last-patient-last-visit to database lock is gated by data cleaning, query resolution, and medical coding — much of it still manual and repetitive. Errors and bottlenecks here ripple into analysis and submission timelines. AI-assisted clinical data management automates anomaly detection, query generation, and coding suggestions so data managers can focus on the cases that genuinely need judgment.
Traditional edit checks catch what someone anticipated; AI-based review also surfaces what nobody wrote a rule for — cross-form inconsistencies, implausible value patterns, site-level anomalies, and duplicate records. Instead of data managers paging through listings, the system produces a prioritized review queue with suggested queries, and the highest-volume clerical work shrinks. Medical coding is the other mature application: models suggest MedDRA and WHODrug codes for reported terms, with coders confirming or correcting. Because the suggestions learn from your coding decisions, consistency tends to improve alongside speed — but a human coder remains in the loop for anything ambiguous.
This is GxP territory, so validation posture decides whether a tool is even eligible: ask for the validation package, 21 CFR Part 11 compliance documentation, audit-trail behavior, and how the vendor supports your own computer-system validation. Any accuracy claim for coding or anomaly detection should be demonstrated on your data during evaluation, not accepted from marketing material. Workflow integration is the second gate: how the tool connects to your EDC, whether flagged issues turn into queries inside your existing system or in a parallel interface, and how the human-review step is documented so responsibility stays clear.
A retrospective pilot on a locked study is the standard low-risk entry: run the tool over data whose issues are already known and measure what it catches, what it misses, and what it flags unnecessarily. That produces a concrete false-positive rate on your own data — the number that determines whether the tool saves review time or creates it.
No — it changes what they spend time on. The repetitive layer of review and query drafting can be heavily automated, but judgment calls, complex discrepancies, and accountability for data integrity remain human responsibilities, and regulated workflows are built around documented human review of AI suggestions.
It can be, when the system runs in a validated environment with audit trails and documented human confirmation of coding decisions. The compliance burden is real but well-trodden — ask vendors for their validation documentation and for reference customers who have taken AI-assisted coding through a regulatory inspection.
Edit checks are pre-programmed rules that fire on anticipated errors. AI review learns patterns from the data itself, so it can flag unanticipated anomalies — a site whose data looks systematically different, values that are individually plausible but jointly unlikely — that no rule would have caught. Most teams run both: rules for the known, models for the unknown.
The mechanism is real — fewer manual review passes, faster query cycles, faster coding — but the size of the gain depends on where your current bottlenecks are. If your lock timeline is gated by site query responsiveness rather than internal review capacity, tooling alone will not fix it. A retrospective pilot is the honest way to estimate impact for your studies.
Syntegra partnered with Datavant to connect its synthetic data engine with Datavant's de-identification and record-linking network, enabling privacy-preserving exchange of synthetic versions of linked real-world health datasets across the healthcare ecosystem.
Vendor: Syntegra · press release (Syntegra (GlobeNewswire)) · 2022-12-15 — Partner: Datavant
Abridge was named the first member of Epic's 'Pals' partnership program, integrating its generative-AI medical conversation summaries directly into Epic EHR workflows so health systems can adopt ambient documentation inside the tools clinicians already use.
Vendor: Abridge · press release (Abridge) · 2023-08-16 — Partner: Epic
Saama's AI-driven clinical analytics supported Pfizer's review of clinical trial data during its COVID-19 vaccine program; the companies subsequently expanded their relationship across Pfizer's broader R&D data operations.
Vendor: Saama Technologies · press release (Saama (Business Wire)) · 2024-02-12 — Partner: Pfizer
Kaiser Permanente rolled out Abridge's ambient AI clinical documentation technology across its integrated health system — 40 hospitals and more than 600 medical offices — letting clinicians generate draft visit notes from patient conversations instead of typing during encounters.
Vendor: Abridge · press release (Kaiser Permanente) · 2024-08-14 — Partner: Kaiser Permanente
A quality-improvement survey at the University of Kansas Medical Center, published in JAMIA Open, reported that clinicians using Abridge's ambient AI documentation self-reported lower perceived work burden and burnout and higher job satisfaction after implementation. Vendor-affiliated authors participated in the study.
Vendor: Abridge · peer reviewed (JAMIA Open (Oxford University Press)) · 2025-02-21